HOPA 2020: Outcomes With Ixazomib-Lenalidomide-Dexamethasone in RRMM Are Comparable Inside and Outside of Clinical Trials
Results should be interpreted with caution due to limited maturity of data, however.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.